The Study Aims to Show Bioequivalence of the Test Product and the Reference Reference Product in a Crossover Design Study Healthy Volunteers. Additionally, the Safeyt Profile of Test Product Compared to Reference Product Will be Assessed.

AET Tiefenbacher Pharmaceuticals

Status: Completed

Conditions: Diabetes Mellitus

Treatments: Drug: Vildagliptin 50 MG

Study type: Interventional

Funder types: Industry

Identifiers

NCT05329844

13-VIN-343

Details and patient eligibility

About

To evaluate and compare the relative bioavailability and therefore the bioequivalence of Vildagliptin Tablets 50 mg of AET Laboratories Private Limited, India, with GALVUS® 50 mg Tablets of Novartis Europharm Limited, United Kingdom, in normal, healthy, adult, male human subjects under fasting conditions and to evaluate the safety and tolerability of Vildagliptin Tablets 50 mg in normal, healthy, adult, male human subjects under fasting conditions.

Enrollment: 66 patients

Sex: Male

Ages: 18 to 45 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

1. Male subjects aged between 18 and 45 years (both inclusive).
2. Subjects' weight within the normal range according to normal values for the Body Mass Index (18.5 to 30 kg/m2) with minimum of 50 kg weight.
3. Subjects with normal health as determined by personal medical history, clinical examination and laboratory examinations within clinically acceptable normal range.
4. Subjects having clinically acceptable 12-lead electrocardiogram (ECG).
5. Subjects having clinically acceptable chest X-Ray.
6. Subjects having negative urine screen for drugs of abuse (including amphetamines, barbiturates, benzodiazepines, marijuana, cocaine and morphine).
7. Subjects having negative alcohol breath test.
8. Subjects willing to adhere to the protocol requirements and to provide written informed consent.
9. No history or presence of smoking.
10. No history or presence of alcoholism and drug of abuse.

Exclusion criteria

1. Hypersensitivity to Vildagliptin or related class of drugs.
2. History or presence of significant cardiovascular, pulmonary, hepatic, renal, gastrointestinal, endocrine, immunological, dermatological, neurological or psychiatric disease or disorder.
3. Any treatment which could bring about induction or inhibition of hepatic microsomal enzyme system within 1 month of the study starting.
4. History or presence of asthma, urticaria or other significant allergic reactions.
5. History or presence of significant gastric and/or duodenal ulceration.
6. History or presence of significant thyroid disease, adrenal dysfunction, organic intracranial lesion such as pituitary tumor.
7. History or presence of cancer.
8. Difficulty with donating blood.
9. Difficulty in swallowing solids like tablets or capsules.
10. Use of any prescribed or OTC medication during last two weeks prior to Dosing in Period 01.
11. Major illness during 3 months before screening.
12. Participation in a drug research study within past 3 months.
13. Donation of blood in the past 3 months before screening.
14. Positive screening test for any one or more: HIV, Hepatitis B and Hepatitis C.
15. History or presence of significant easy bruising or bleeding.
16. History or presence of significant recent trauma.
17. Subjects who have been on an abnormal diet (for whatever reason) during the four weeks preceding the study.

Trial design

Primary purpose: Other

Allocation: Randomized

Interventional model: Crossover Assignment

Masking: None (Open label)

---

66 participants in 2 patient groups

Vildagliptin 50 mg Tablet

Experimental group

Description:

1 tablet of Vildagliptin 50 mg as single-dose administration

Treatment:

Drug: Vildagliptin 50 MG

Galvus 50 mg Tablet

Active Comparator group

Description:

1 tablet of Galvus 50 mg (each tablet contains 50 mg Vildagliptin) as single-dose administration

Treatment:

Drug: Vildagliptin 50 MG